Key Points
- COO Jeremy Chadwick sold 91,250 shares on March 23 at an average of $77.41 for a total of about $7.06M, leaving him with 61,202 shares (a 59.85% reduction in his position).
- Additional insider sales (24,727 shares on March 25 at ~$80.26) bring the combined total to roughly 116,000 shares sold for ~$9M, materially cutting his stake and posing a potential near-term headwind for the stock.
- Kymera shares opened near $78.93 with a market cap of $6.44B, but the company recently missed EPS and reported a 60.8% YoY revenue decline; analysts maintain an average rating of "Moderate Buy" with an average price target of $118.90.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 24,727 shares of Kymera Therapeutics stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $80.26, for a total transaction of $1,984,589.02. Following the completion of the transaction, the chief operating officer directly owned 61,202 shares of the company's stock, valued at approximately $4,912,072.52. This represents a 28.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Kymera Therapeutics Price Performance
KYMR stock opened at $78.93 on Thursday. The firm has a market cap of $6.44 billion, a price-to-earnings ratio of -21.45 and a beta of 2.20. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The firm has a fifty day moving average price of $79.87 and a two-hundred day moving average price of $70.36.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business had revenue of $2.87 million during the quarter, compared to the consensus estimate of $14.80 million. During the same quarter in the previous year, the business posted ($0.88) earnings per share. The company's quarterly revenue was down 60.8% compared to the same quarter last year. As a group, analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Hedge Funds Weigh In On Kymera Therapeutics
Several large investors have recently bought and sold shares of the stock. US Bancorp DE increased its stake in Kymera Therapeutics by 9.8% during the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company's stock valued at $106,000 after buying an additional 166 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Kymera Therapeutics by 9.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company's stock worth $156,000 after acquiring an additional 248 shares during the period. Larson Financial Group LLC boosted its holdings in shares of Kymera Therapeutics by 36.9% in the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company's stock valued at $83,000 after acquiring an additional 287 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in shares of Kymera Therapeutics by 3.3% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 12,655 shares of the company's stock valued at $985,000 after acquiring an additional 410 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock valued at $42,000 after acquiring an additional 424 shares during the period.
Kymera Therapeutics News Roundup
Here are the key news stories impacting Kymera Therapeutics this week:
- Positive Sentiment: Brokerage sentiment: multiple brokerages are summarized as a consensus "Moderate Buy," which can support demand from institutional and retail investors. Article Title
- Neutral Sentiment: Short-interest filings dated March 24 report 0 shares short and a 0.0 days-to-cover ratio across several notices — likely a data anomaly or timing artifact, so this does not provide a clear bullish or bearish signal.
- Negative Sentiment: Insider selling — COO Jeremy G. Chadwick sold 91,250 shares on March 23 at ~$77.41 (~$7.06M). The SEC filing is available here: SEC Filing
- Negative Sentiment: Additional insider selling — Chadwick sold 24,727 shares on March 25 at ~$80.26 (~$1.98M). Combined with the March 23 sale, roughly 116k shares were sold for ~ $9.0M, materially reducing his reported stake — a potential near-term headwind for the stock. SEC filing: SEC Filing
Analysts Set New Price Targets
KYMR has been the subject of a number of research reports. B. Riley Financial lifted their target price on Kymera Therapeutics from $80.00 to $117.00 and gave the company a "buy" rating in a research note on Monday, December 22nd. Stephens increased their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an "overweight" rating in a research report on Monday, March 2nd. Truist Financial raised their price target on Kymera Therapeutics from $80.00 to $116.00 and gave the stock a "buy" rating in a report on Tuesday, December 9th. Royal Bank Of Canada restated an "outperform" rating and set a $108.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Finally, Wall Street Zen downgraded Kymera Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $118.90.
Check Out Our Latest Report on Kymera Therapeutics
About Kymera Therapeutics
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
